Sangamo Therapeutics (SGMO) Competitors $0.50 +0.00 (+0.12%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMO vs. RGLS, ZBIO, MYGN, VSTM, RIGL, EBS, XOMA, LXRX, VNDA, and CDXSShould you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Sangamo Therapeutics vs. Regulus Therapeutics Zenas Biopharma Myriad Genetics Verastem Rigel Pharmaceuticals Emergent BioSolutions XOMA Lexicon Pharmaceuticals Vanda Pharmaceuticals Codexis Regulus Therapeutics (NASDAQ:RGLS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Which has better valuation and earnings, RGLS or SGMO? Regulus Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$0.73-10.89Sangamo Therapeutics$63.76M1.83-$257.83M-$0.39-1.28 Does the media refer more to RGLS or SGMO? In the previous week, Sangamo Therapeutics had 9 more articles in the media than Regulus Therapeutics. MarketBeat recorded 13 mentions for Sangamo Therapeutics and 4 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 0.90 beat Sangamo Therapeutics' score of 0.67 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regulus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is RGLS or SGMO more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. Regulus Therapeutics' return on equity of -53.07% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Sangamo Therapeutics -257.87%-264.16%-107.24% Do analysts recommend RGLS or SGMO? Regulus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 6.92%. Sangamo Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 801.62%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29Sangamo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor RGLS or SGMO? Regulus Therapeutics received 37 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 63.33% of users gave Regulus Therapeutics an outperform vote while only 62.77% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49463.33% Underperform Votes28636.67% Sangamo TherapeuticsOutperform Votes45762.77% Underperform Votes27137.23% Do insiders & institutionals have more ownership in RGLS or SGMO? 92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, RGLS or SGMO? Regulus Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. SummaryRegulus Therapeutics beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks. Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMO vs. The Competition Export to ExcelMetricSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.37M$2.97B$5.43B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.6731.5826.8320.05Price / Sales1.83414.63394.87116.44Price / Cash30.42168.6838.2534.62Price / Book1.063.376.874.61Net Income-$257.83M-$72.17M$3.22B$248.19M7 Day Performance13.95%18.10%6.82%2.97%1 Month Performance-32.19%20.85%13.72%16.58%1 Year Performance-16.45%-24.45%18.31%8.16% Sangamo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMOSangamo Therapeutics1.9123 of 5 stars$0.50+0.1%$4.50+801.6%-18.8%$116.37M$63.76M-0.67480Analyst RevisionRGLSRegulus Therapeutics1.3373 of 5 stars$7.87-0.1%$8.50+8.1%+295.5%$521.00MN/A-7.3530Analyst ForecastZBIOZenas BiopharmaN/A$9.74+7.6%$40.00+310.7%N/A$407.46M$5M-2.74N/ATrending NewsEarnings ReportAnalyst RevisionGap UpMYGNMyriad Genetics4.1131 of 5 stars$4.26+9.5%$16.04+276.4%-82.2%$392.67M$837.60M-3.282,600Gap UpHigh Trading VolumeVSTMVerastem3.1764 of 5 stars$7.26+1.2%$14.33+97.5%-30.8%$373.71M$10M-2.2850Insider TradeRIGLRigel Pharmaceuticals2.8616 of 5 stars$18.65-0.7%$36.40+95.2%+110.7%$333.13M$179.28M133.19160Positive NewsEBSEmergent BioSolutions4.4785 of 5 stars$5.85+3.6%$14.33+144.9%+19.7%$318.03M$1.01B-1.432,420Analyst RevisionXOMAXOMA4.1728 of 5 stars$24.89+2.9%$69.50+179.2%+6.3%$297.56M$10.22M-7.1510News CoverageInsider TradeAnalyst RevisionGap UpLXRXLexicon Pharmaceuticals3.2436 of 5 stars$0.68-3.6%$3.67+442.4%-67.8%$244.37M$31.08M-0.90140VNDAVanda Pharmaceuticals4.4247 of 5 stars$4.05+2.4%$16.50+307.9%-15.7%$238.39M$198.77M-12.64290CDXSCodexis3.4097 of 5 stars$2.63+6.9%$8.00+204.3%-27.9%$217.80M$59.35M-3.02250Positive NewsEarnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies RGLS Alternatives ZBIO Alternatives MYGN Alternatives VSTM Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives LXRX Alternatives VNDA Alternatives CDXS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SGMO Stock Free SGMO Stock Alerts